{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T03:42:45Z","timestamp":1791517365600,"version":"4.3.4"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2021,9,13]],"date-time":"2021-09-13T00:00:00Z","timestamp":1631491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,9,13]],"date-time":"2021-09-13T00:00:00Z","timestamp":1631491200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001711","name":"schweizerischer nationalfonds zur f\u00f6rderung der wissenschaftlichen forschung","doi-asserted-by":"publisher","award":["32003B_185111"],"award-info":[{"award-number":["32003B_185111"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008375","name":"Universit\u00e4t Basel","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100008375","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Psychopharmacology"],"published-print":{"date-parts":[[2022,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Rationale<\/jats:title>\n                <jats:p>Lysergic acid diethylamide (LSD) is used in psychiatric and psychological research and investigated as a potential treatment for medical and psychiatric disorders, including depression, anxiety, and cluster headache.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Objectives<\/jats:title>\n                <jats:p>Safety data on clinical safety are available from small studies but not from larger samples. We report safety pharmacology data from a large pooled study sample on acute effects of LSD in healthy subjects.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We conducted a pooled analysis of four double-blind, randomized, placebo-controlled, crossover studies that included a total of 83 healthy subjects and 131 single-dose administrations of LSD. LSD administrations were matched to dose groups according to measured LSD peak plasma concentrations to adjust for uncertainties in the correct LSD dose in some studies. Single doses were 25, 50, 100, and 200\u00a0\u00b5g of LSD base. We investigated subjective effects (self-rated any drug effect, good drug effect, bad drug effect, and anxiety), blood pressure, heart rate, body temperature, duration of the acute LSD response, acute (12\u00a0h) and subacute (24\u00a0h) adverse effects, reports of flashbacks, and liver and kidney function before and after the studies.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>LSD dose-dependently increased subjective, physiologic, and adverse effects. The dose\u2013response curves for the proportions of subjects with a certain amount of a subjective effect were steeper and reached a higher maximum for positive acute subjective effects compared with negative acute subjective effects. Maximal ratings of\u2009&gt;\u200950% good drug effects were reached in 37%, 91%, 96%, and 91% of the LSD administrations at 25, 50, 100, and 200\u00a0\u00b5g. Maximal ratings of\u2009&gt;\u200950% bad drug effects were reached in 0%, 9%, 27%, 31% at 25, 50, 100, and 200\u00a0\u00b5g, respectively. Mean ratings of Oceanic Boundlessness were 10%, 25%, 41%, and 44%, and mean ratings of Anxious Ego-Dissolution were 3.4%, 13%, 20%, and 22% at 25, 50, 100, and 200\u00a0\u00b5g, respectively. The physiologic effects of LSD were moderate. None of the subjects had systolic blood pressure\u2009&gt;\u2009180\u00a0mmHg at any time. Peak heart rate\u2009&gt;\u2009100 beats\/min was observed in 0%, 6%, 20%, and 25% of the subjects at 25, 50, 100, and 200\u00a0\u00b5g, respectively. Maximal heart rates of 129 and 121 beats\/min were observed in one subject at the 50 and 200\u00a0\u00b5g doses, respectively. Peak body temperature\u2009&gt;\u200938\u00b0 was observed in 0%, 11%, 7%, and 34% at 25, 50, 100, and 200\u00a0\u00b5g, respectively. Mean acute adverse effect scores on the List of Complaints were 5.6, 9.2, 12, and 13 at 25, 50, 100, and 200\u00a0\u00b5g, respectively. Kidney and liver function parameters were unaltered. Six subjects reported transient flashback phenomena.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The single-dose administration of LSD is safe in regard to acute psychological and physical harm in healthy subjects in a controlled research setting.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00213-021-05978-6","type":"journal-article","created":{"date-parts":[[2021,9,13]],"date-time":"2021-09-13T06:02:37Z","timestamp":1631512957000},"page":"1893-1905","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":50,"title":["Safety pharmacology of acute LSD administration in healthy subjects"],"prefix":"10.1007","volume":"239","author":[{"given":"Friederike","family":"Holze","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toya V.","family":"Caluori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Vizeli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias E.","family":"Liechti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,9,13]]},"reference":[{"issue":"2","key":"5978_CR1","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1111\/acps.13249","volume":"143","author":"KAA Andersen","year":"2021","unstructured":"Andersen KAA, Carhart-Harris R, Nutt DJ, Erritzoe D (2021) Therapeutic effects of classic serotonergic psychedelics: a systematic review of modern-era clinical studies. Acta Psychiatr Scand 143(2):101\u2013118","journal-title":"Acta Psychiatr Scand"},{"issue":"12","key":"5978_CR2","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1177\/0269881116678781","volume":"30","author":"FS Barrett","year":"2016","unstructured":"Barrett FS, Bradstreet MP, Leoutsakos JS, Johnson MW, Griffiths RR (2016) The Challenging Experience Questionnaire: characterization of challenging experiences with psilocybin mushrooms. J Psychopharmacol 30(12):1279\u20131295","journal-title":"J Psychopharmacol"},{"key":"5978_CR3","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.paid.2017.06.004","volume":"117","author":"FS Barrett","year":"2017","unstructured":"Barrett FS, Johnson MW, Griffiths RR (2017) Neuroticism is associated with challenging experiences with psilocybin mushrooms. Pers Individ Dif 117:155\u2013160","journal-title":"Pers Individ Dif"},{"issue":"7","key":"5978_CR4","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1111\/j.1360-0443.2006.01423.x","volume":"101","author":"CA Baylen","year":"2006","unstructured":"Baylen CA, Rosenberg H (2006) A review of the acute subjective effects of MDMA\/ecstasy. Addiction 101(7):933\u2013947","journal-title":"Addiction"},{"issue":"10","key":"5978_CR5","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1038\/s41386-019-0402-z","volume":"44","author":"AK Bershad","year":"2019","unstructured":"Bershad AK, Mayo LM, Van Hedger K, McGlone F, Walker SC, de Wit H (2019) Effects of MDMA on attention to positive social cues and pleasantness of affective touch. Neuropsychopharmacol 44(10):1698\u20131705","journal-title":"Neuropsychopharmacol"},{"issue":"4","key":"5978_CR6","first-page":"461","volume":"5","author":"AK Bershad","year":"2020","unstructured":"Bershad AK, Preller KH, Lee R, Keedy S, Wren-Jarvis J, Bremmer MP, de Wit H (2020) Preliminary report on the effects of a low dose of LSD on resting-state amygdala functional connectivity. Biol Psychiatry Cogn Neurosci Neuroimaging 5(4):461\u2013467","journal-title":"Biol Psychiatry Cogn Neurosci Neuroimaging"},{"issue":"10","key":"5978_CR7","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/j.biopsych.2019.05.019","volume":"86","author":"AK Bershad","year":"2019","unstructured":"Bershad AK, Schepers ST, Bremmer MP, Lee R, de Wit H (2019) Acute subjective and behavioral effects of microdoses of lysergic acid diethylamide in healthy human volunteers. Biol Psychiatry 86(10):792\u2013800","journal-title":"Biol Psychiatry"},{"issue":"12","key":"5978_CR8","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1177\/0269881116662634","volume":"30","author":"TM Carbonaro","year":"2016","unstructured":"Carbonaro TM, Bradstreet MP, Barrett FS, MacLean KA, Jesse R, Johnson MW, Griffiths RR (2016) Survey study of challenging experiences after ingesting psilocybin mushrooms: acute and enduring positive and negative consequences. J Psychopharmacol 30(12):1268\u20131278","journal-title":"J Psychopharmacol"},{"issue":"2","key":"5978_CR9","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1007\/s00213-017-4769-4","volume":"235","author":"TM Carbonaro","year":"2018","unstructured":"Carbonaro TM, Johnson MW, Hurwitz E, Griffiths RR (2018) Double-blind comparison of the two hallucinogens psilocybin and dextromethorphan: similarities and differences in subjective experiences. Psychopharmacol 235(2):521\u2013534","journal-title":"Psychopharmacol"},{"key":"5978_CR10","doi-asserted-by":"crossref","first-page":"4853","DOI":"10.1073\/pnas.1518377113","volume":"113","author":"RL Carhart-Harris","year":"2016","unstructured":"Carhart-Harris RL, Muthukumaraswamy S, Roseman L, Kaelen M, Droog W, Murphy K, Tagliazucchi E, Schenberg EE, Nest T, Orban C, Leech R, Williams LT, Williams TM, Bolstridge M, Sessa B, McGonigle J, Sereno MI, Nichols D, Hellyer PJ, Hobden P, Evans J, Singh KD, Wise RG, Curran HV, Feilding A, Nutt DJ (2016) Neural correlates of the LSD experience revealed by multimodal neuroimaging. Proc Natl Acad Sci U S A 113:4853\u20134858","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"Suppl 2","key":"5978_CR11","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1055\/s-2007-979351","volume":"31","author":"A Dittrich","year":"1998","unstructured":"Dittrich A (1998) The standardized psychometric assessment of altered states of consciousness (ASCs) in humans. Pharmacopsychiatry 31(Suppl 2):80\u201384","journal-title":"Pharmacopsychiatry"},{"key":"5978_CR12","doi-asserted-by":"publisher","first-page":"pyv072","DOI":"10.1093\/ijnp\/pyv072","volume":"19","author":"PC Dolder","year":"2015","unstructured":"Dolder PC, Schmid Y, Haschke M, Rentsch KM, Liechti ME (2015) Pharmacokinetics and concentration-effect relationship of oral LSD in humans. Int J Neuropsychopharmacol 19:pyv072","journal-title":"Int J Neuropsychopharmacol"},{"key":"5978_CR13","doi-asserted-by":"publisher","first-page":"2638","DOI":"10.1038\/npp.2016.82","volume":"41","author":"PC Dolder","year":"2016","unstructured":"Dolder PC, Schmid Y, Mueller F, Borgwardt S, Liechti ME (2016) LSD acutely impairs fear recognition and enhances emotional empathy and sociality. Neuropsychopharmacology 41:2638\u20132646","journal-title":"Neuropsychopharmacology"},{"key":"5978_CR14","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1007\/s40262-017-0513-9","volume":"56","author":"PC Dolder","year":"2017","unstructured":"Dolder PC, Schmid Y, Steuer AE, Kraemer T, Rentsch KM, Hammann F, Liechti ME (2017) Pharmacokinetics and pharmacodynamics of lysergic acid diethylamide in healthy subjects. Clin Pharmacokinetics 56:1219\u20131230","journal-title":"Clin Pharmacokinetics"},{"issue":"3","key":"5978_CR15","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1007\/s00213-019-05417-7","volume":"237","author":"N Family","year":"2020","unstructured":"Family N, Maillet EL, Williams LTJ, Krediet E, Carhart-Harris RL, Williams TM, Nichols CD, Goble DJ, Raz S (2020) Safety, tolerability, pharmacokinetics, and pharmacodynamics of low dose lysergic acid diethylamide (LSD) in healthy older volunteers. Psychopharmacology 237(3):841\u2013853","journal-title":"Psychopharmacology"},{"key":"5978_CR16","unstructured":"Gasser P (2017) Research update: psychedelic group therapy in Switzerland. MAPS Bulletin, vol 27."},{"issue":"7","key":"5978_CR17","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1097\/NMD.0000000000000113","volume":"202","author":"P Gasser","year":"2014","unstructured":"Gasser P, Holstein D, Michel Y, Doblin R, Yazar-Klosinski B, Passie T, Brenneisen R (2014) Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases. J Nerv Ment Dis 202(7):513\u2013520","journal-title":"J Nerv Ment Dis"},{"issue":"1","key":"5978_CR18","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1177\/0269881114555249","volume":"29","author":"P Gasser","year":"2015","unstructured":"Gasser P, Kirchner K, Passie T (2015) LSD-assisted psychotherapy for anxiety associated with a life-threatening disease: a qualitative study of acute and sustained subjective effects. J Psychopharmacol 29(1):57\u201368","journal-title":"J Psychopharmacol"},{"issue":"12","key":"5978_CR19","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1177\/0269881116675513","volume":"30","author":"RR Griffiths","year":"2016","unstructured":"Griffiths RR, Johnson MW, Carducci MA, Umbricht A, Richards WA, Richards BD, Cosimano MP, Klinedinst MA (2016) Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial. J Psychopharmacol 30(12):1181\u20131197","journal-title":"J Psychopharmacol"},{"issue":"5","key":"5978_CR20","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1017\/S1481803500012598","volume":"12","author":"BE Grunau","year":"2010","unstructured":"Grunau BE, Wiens MO, Brubacher JR (2010) Dantrolene in the treatment of MDMA-related hyperpyrexia: a systematic review. CJEM 12(5):435\u2013442","journal-title":"CJEM"},{"key":"5978_CR21","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/7854_2016_457","volume":"36","author":"JH Halpern","year":"2016","unstructured":"Halpern JH, Lerner AG, Passie T (2016) A review of hallucinogen persisting perception disorder (HPPD) and an exploratory study of subjects claiming symptoms of HPPD. Curr Top Behav Neurosci 36:333\u2013360","journal-title":"Curr Top Behav Neurosci"},{"issue":"4","key":"5978_CR22","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1177\/0960327110370984","volume":"30","author":"P Halpern","year":"2011","unstructured":"Halpern P, Moskovich J, Avrahami B, Bentur Y, Soffer D, Peleg K (2011) Morbidity associated with MDMA (ecstasy) abuse: a survey of emergency department admissions. Hum Exp Toxicol 30(4):259\u2013266","journal-title":"Hum Exp Toxicol"},{"issue":"12","key":"5978_CR23","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1177\/0269881116677852","volume":"30","author":"I Hartogsohn","year":"2016","unstructured":"Hartogsohn I (2016) Set and setting, psychedelics and the placebo response: an extra-pharmacological perspective on psychopharmacology. J Psychopharmacol 30(12):1259\u20131267","journal-title":"J Psychopharmacol"},{"issue":"8816","key":"5978_CR24","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/0140-6736(92)91469-O","volume":"340","author":"JA Henry","year":"1992","unstructured":"Henry JA, Jeffreys KJ, Dawling S (1992) Toxicity and deaths from 3,4-methylenedioxymethamphetamine (\u201cecstasy\u201d). Lancet 340(8816):384\u2013387","journal-title":"Lancet"},{"issue":"1","key":"5978_CR25","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1124\/jpet.300.1.236","volume":"300","author":"C Hernandez-Lopez","year":"2002","unstructured":"Hernandez-Lopez C, Farre M, Roset PN, Menoyo E, Pizarro N, Ortuno J, Torrens M, Cami J, de La Torre R (2002) 3,4-Methylenedioxymethamphetamine (ecstasy) and alcohol interactions in humans: psychomotor performance, subjective effects, and pharmacokinetics. J Pharmacol Exp Ther 300(1):236\u2013244","journal-title":"J Pharmacol Exp Ther"},{"issue":"4","key":"5978_CR26","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1177\/0269881121992676","volume":"35","author":"T Hirschfeld","year":"2021","unstructured":"Hirschfeld T, Schmidt TT (2021) Dose-response relationships of psilocybin-induced subjective experiences in humans. J Psychopharmacol 35(4):384\u2013397","journal-title":"J Psychopharmacol"},{"key":"5978_CR27","volume-title":"Flaschback-Ph\u00e4nomene","author":"D Holland","year":"2011","unstructured":"Holland D, Passie T (2011) Flaschback-Ph\u00e4nomene. Verlag f\u00fcr Wissenschaft und Bildung, Berlin"},{"key":"5978_CR28","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1111\/bcp.13918","volume":"85","author":"F Holze","year":"2019","unstructured":"Holze F, Duthaler U, Vizeli P, Muller F, Borgwardt S, Liechti ME (2019) Pharmacokinetics and subjective effects of a novel oral LSD formulation in healthy subjects. Br J Clin Pharmacol 85:1474\u20131483","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"5978_CR29","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1002\/cpt.2057","volume":"109","author":"F Holze","year":"2021","unstructured":"Holze F, Liechti ME, Hutten N, Mason NL, Dolder PC, Theunissen EL, Duthaler U, Feilding A, Ramaekers JG, Kuypers KPC (2021) Pharmacokinetics and pharmacodynamics of lysergic acid diethylamide microdoses in healthy participants. Clin Pharmacol Ther 109(3):658\u2013666","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"5978_CR30","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1038\/s41386-020-00883-6","volume":"46","author":"F Holze","year":"2021","unstructured":"Holze F, Vizeli P, Ley L, Muller F, Dolder P, Stocker M, Duthaler U, Varghese N, Eckert A, Borgwardt S, Liechti ME (2021) Acute dose-dependent effects of lysergic acid diethylamide in a double-blind placebo-controlled study in healthy subjects. Neuropsychopharmacology 46(3):537\u2013544","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"5978_CR31","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1038\/s41386-019-0569-3","volume":"45","author":"F Holze","year":"2020","unstructured":"Holze F, Vizeli P, Muller F, Ley L, Duerig R, Varghese N, Eckert A, Borgwardt S, Liechti ME (2020) Distinct acute effects of LSD, MDMA, and D-amphetamine in healthy subjects. Neuropsychopharmacology 45(3):462\u2013471","journal-title":"Neuropsychopharmacology"},{"key":"5978_CR32","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.euroneuro.2020.10.002","volume":"41","author":"N Hutten","year":"2020","unstructured":"Hutten N, Mason NL, Dolder PC, Theunissen EL, Holze F, Liechti ME, Feilding A, Ramaekers JG, Kuypers KPC (2020) Mood and cognition after administration of low LSD doses in healthy volunteers: a placebo controlled dose-effect finding study. Eur Neuropsychopharmacol 41:81\u201391","journal-title":"Eur Neuropsychopharmacol"},{"key":"5978_CR33","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1124\/jpet.111.188425","volume":"340","author":"CM Hysek","year":"2012","unstructured":"Hysek CM, Brugger R, Simmler LD, Bruggisser M, Donzelli M, Grouzmann E, Hoener MC, Liechti ME (2012) Effects of the \u03b12-adrenergic agonist clonidine on the pharmacodynamics and pharmacokinetics of 3,4-methylenedioxymethamphetamine in healthy volunteers. J Pharmacol Exp Ther 340:286\u2013294","journal-title":"J Pharmacol Exp Ther"},{"issue":"S3","key":"5978_CR34","doi-asserted-by":"publisher","first-page":"S240","DOI":"10.1016\/S0924-977X(10)70296-0","volume":"20","author":"CM Hysek","year":"2010","unstructured":"Hysek CM, Ineichen M, Nicola VG, Simmler LD, Liechti ME (2010) Role of the norepinephrine uptake transporter in the mechanism of action of MDMA (Ecstasy). Eur Neuropsychopharmacol 20(S3):S240","journal-title":"Eur Neuropsychopharmacol"},{"issue":"5","key":"5978_CR35","doi-asserted-by":"publisher","first-page":"e36476","DOI":"10.1371\/journal.pone.0036476","volume":"7","author":"CM Hysek","year":"2012","unstructured":"Hysek CM, Simmler LD, Nicola VG, Vischer N, Donzelli M, Krahenbuhl S, Grouzmann E, Huwyler J, Hoener MC, Liechti ME (2012) Duloxetine inhibits effects of MDMA ecstasy in vitro and in humans in a randomized placebo controlled laboratory study. PLoS One 7(5):e36476","journal-title":"PLoS One"},{"key":"5978_CR36","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1093\/scan\/nst161","volume":"9","author":"CM Hysek","year":"2014","unstructured":"Hysek CM, Schmid Y, Simmler LD, Domes G, Heinrichs M, Eisenegger C, Preller KH, Quednow BB, Liechti ME (2014) MDMA enhances emotional empathy and prosocial behavior. Soc Cogn Affect Neurosci 9:1645\u20131652","journal-title":"Soc Cogn Affect Neurosci"},{"issue":"6","key":"5978_CR37","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1177\/0269881108093587","volume":"22","author":"M Johnson","year":"2008","unstructured":"Johnson M, Richards W, Griffiths R (2008) Human hallucinogen research: guidelines for safety. J Psychopharmacol 22(6):603\u2013620","journal-title":"J Psychopharmacol"},{"key":"5978_CR38","doi-asserted-by":"publisher","first-page":"179","DOI":"10.4161\/23328940.2014.955433","volume":"1","author":"ME Liechti","year":"2014","unstructured":"Liechti ME (2014) Effects of MDMA on body temperature in humans. Temperature 1:179\u2013187","journal-title":"Temperature"},{"key":"5978_CR39","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1007\/s00213-016-4453-0","volume":"234","author":"ME Liechti","year":"2017","unstructured":"Liechti ME, Dolder PC, Schmid Y (2017) Alterations in conciousness and mystical-type experiences after acute LSD in humans. Psychopharmacology 234:1499\u20131510","journal-title":"Psychopharmacology"},{"issue":"43\u201344","key":"5978_CR40","first-page":"652","volume":"135","author":"ME Liechti","year":"2005","unstructured":"Liechti ME, Kunz I, Kupferschmidt H (2005) Acute medical problems due to Ecstasy use: case-series of emergency department visits. Swiss Med Wkly 135(43\u201344):652\u2013657","journal-title":"Swiss Med Wkly"},{"issue":"3","key":"5978_CR41","doi-asserted-by":"publisher","first-page":"47","DOI":"10.3390\/brainsci8030047","volume":"8","author":"G Martinotti","year":"2018","unstructured":"Martinotti G, Santacroce R, Pettorruso M, Montemitro C, Spano MC, Lorusso M, di Giannantonio M, Lerner AG (2018) Hallucinogen persisting perception disorder: etiology, clinical features, and therapeutic perspectives. Brain Sci 8(3):47","journal-title":"Brain Sci"},{"issue":"2","key":"5978_CR42","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1124\/pr.115.011478","volume":"68","author":"DE Nichols","year":"2016","unstructured":"Nichols DE (2016) Psychedelics. Pharmacol Rev 68(2):264\u2013355","journal-title":"Pharmacol Rev"},{"issue":"4","key":"5978_CR43","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1111\/j.1755-5949.2008.00059.x","volume":"14","author":"T Passie","year":"2008","unstructured":"Passie T, Halpern JH, Stichtenoth DO, Emrich HM, Hintzen A (2008) The pharmacology of lysergic acid diethylamide: a review. CNS Neurosci Ther 14(4):295\u2013314","journal-title":"CNS Neurosci Ther"},{"key":"5978_CR44","doi-asserted-by":"publisher","first-page":"974","DOI":"10.3389\/fphar.2017.00974","volume":"8","author":"L Roseman","year":"2017","unstructured":"Roseman L, Nutt DJ, Carhart-Harris RL (2017) Quality of acute psychedelic experience predicts therapeutic efficacy of psilocybin for treatment-resistant depression. Front Pharmacol 8:974","journal-title":"Front Pharmacol"},{"issue":"12","key":"5978_CR45","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1177\/0269881116675512","volume":"30","author":"S Ross","year":"2016","unstructured":"Ross S, Bossis A, Guss J, Agin-Liebes G, Malone T, Cohen B, Mennenga SE, Belser A, Kalliontzi K, Babb J, Su Z, Corby P, Schmidt BL (2016) Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. J Psychopharmacol 30(12):1165\u20131180","journal-title":"J Psychopharmacol"},{"issue":"8","key":"5978_CR46","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1016\/j.biopsych.2014.11.015","volume":"78","author":"Y Schmid","year":"2015","unstructured":"Schmid Y, Enzler F, Gasser P, Grouzmann E, Preller KH, Vollenweider FX, Brenneisen R, Mueller F, Borgwardt S, Liechti ME (2015) Acute effects of lysergic acid diethylamide in healthy subjects. Biol Psychiatry 78(8):544\u2013553","journal-title":"Biol Psychiatry"},{"issue":"4","key":"5978_CR47","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1177\/0269881120959604","volume":"35","author":"Y Schmid","year":"2021","unstructured":"Schmid Y, Gasser P, Oehen P, Liechti ME (2021) Acute subjective effects in LSD- and MDMA-assisted psychotherapy. J Psychopharmacol 35(4):362\u2013374","journal-title":"J Psychopharmacol"},{"issue":"2","key":"5978_CR48","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1007\/s00213-017-4733-3","volume":"235","author":"Y Schmid","year":"2018","unstructured":"Schmid Y, Liechti ME (2018) Long-lasting subjective effects of LSD in normal subjects. Psychopharmacology 235(2):535\u2013545","journal-title":"Psychopharmacology"},{"key":"5978_CR49","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1002\/dta.2042","volume":"9","author":"AE Steuer","year":"2017","unstructured":"Steuer AE, Poetzsch M, Stock L, Eisenbeiss L, Schmid Y, Liechti ME, Kraemer T (2017) Development and validation of an ultra-fast and sensitive microflow liquid chromatography-tandem mass spectrometry (MFLC-MS\/MS) method for quantification of LSD and its metabolites in plasma and application to a controlled LSD administration study in humans. Drug Test Anal 9:788\u2013797","journal-title":"Drug Test Anal"},{"key":"5978_CR50","doi-asserted-by":"crossref","unstructured":"Studerus E, Gamma A, Kometer M, Vollenweider FX (2012) Prediction of psilocybin response in healthy volunteers. PLoS One 7(2):e30800.","DOI":"10.1371\/journal.pone.0030800"},{"key":"5978_CR51","doi-asserted-by":"crossref","unstructured":"Studerus E, Gamma A, Vollenweider FX (2010) Psychometric evaluation of the altered states of consciousness rating scale (OAV). PLoS One 5(8):e12412.","DOI":"10.1371\/journal.pone.0012412"},{"issue":"5","key":"5978_CR52","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1177\/0269881117691569","volume":"31","author":"P Vizeli","year":"2017","unstructured":"Vizeli P, Liechti ME (2017) Safety pharmacology of acute MDMA administration in healthy subjects. J Psychopharmacol 31(5):576\u2013588","journal-title":"J Psychopharmacol"},{"issue":"1","key":"5978_CR53","doi-asserted-by":"publisher","first-page":"10851","DOI":"10.1038\/s41598-021-90343-y","volume":"11","author":"P Vizeli","year":"2021","unstructured":"Vizeli P, Straumann I, Holze F, Schmid Y, Dolder PC, Liechti ME (2021) Genetic influence of CYP2D6 on pharmacokinetics and acute subjective effects of LSD in a pooled analysis. Sci Rep 11(1):10851","journal-title":"Sci Rep"},{"key":"5978_CR54","volume-title":"Hospital emergency presentations and acute drug toxicity in Europe: update from the Euro-DEN Plus research group and the EMCDDA","author":"DM Wood","year":"2016","unstructured":"Wood DM, Giraudon I, Mounteney J, Dargan PI (2016) Hospital emergency presentations and acute drug toxicity in Europe: update from the Euro-DEN Plus research group and the EMCDDA. European Monitoring Centre for Drugs and Drug Addiction, Lisbon"},{"issue":"4","key":"5978_CR55","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1007\/s00213-018-5119-x","volume":"236","author":"S Yanakieva","year":"2019","unstructured":"Yanakieva S, Polychroni N, Family N, Williams LTJ, Luke DP, Terhune DB (2019) The effects of microdose LSD on time perception: a randomised, double-blind, placebo-controlled trial. Psychopharmacol 236(4):1159\u20131170","journal-title":"Psychopharmacol"},{"key":"5978_CR56","unstructured":"Zerssen DV (1976) Die Beschwerden-Liste. M\u00fcnchener Informationssystem. Psychis, M\u00fcnchen."}],"updated-by":[{"DOI":"10.1007\/s00213-021-05988-4","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2021,9,27]],"date-time":"2021-09-27T00:00:00Z","timestamp":1632700800000}}],"container-title":["Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-021-05978-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00213-021-05978-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-021-05978-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,3]],"date-time":"2022-06-03T07:06:06Z","timestamp":1654239966000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00213-021-05978-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,13]]},"references-count":56,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["5978"],"URL":"https:\/\/doi.org\/10.1007\/s00213-021-05978-6","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s00213-021-05988-4","asserted-by":"object"}]},"ISSN":["0033-3158","1432-2072"],"issn-type":[{"value":"0033-3158","type":"print"},{"value":"1432-2072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,13]]},"assertion":[{"value":"6 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2021","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s00213-021-05988-4","URL":"https:\/\/doi.org\/10.1007\/s00213-021-05988-4","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"MEL is a consultant for Mind Medicine, Inc. The other authors declare no conflicts of interests. Knowhow and data associated with this work and owned by the University Hospital Basel were licensed by Mind Medicine, Inc. Mind Medicine, Inc. had no role in financing, planning, or conducting the present study or the present publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}